Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.4644 USD
−18.69 M USD
34.75 K USD
25.47 M
About BERGENBIO ASA
Sector
CEO
Olav Hellebø
Headquarters
Bergen
Website
Founded
2007
ISIN
NO0013251173
FIGI
BBG00LGDWPS6
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BRRGF is 2.5000 USD — it has decreased by −98.59% in the past 24 hours. Watch Bergenbio AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Bergenbio AS stocks are traded under the ticker BRRGF.
We've gathered analysts' opinions on Bergenbio AS future price: according to them, BRRGF price has a max estimate of 3.43 USD and a min estimate of 1.54 USD. Watch BRRGF chart and read a more detailed Bergenbio AS stock forecast: see what analysts think of Bergenbio AS and suggest that you do with its stocks.
BRRGF reached its all-time high on May 22, 2020 with the price of 439.0000 USD, and its all-time low was 2.5000 USD and was reached on Nov 29, 2023. View more price dynamics on BRRGF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BRRGF stock is 6.98 K% volatile and has beta coefficient of 0.82. Track Bergenbio AS stock price on the chart and check out the list of the most volatile stocks — is Bergenbio AS there?
Today Bergenbio AS has the market capitalization of 28.51 M, it has increased by 6.23% over the last week.
Yes, you can track Bergenbio AS financials in yearly and quarterly reports right on TradingView.
Bergenbio AS is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
BRRGF earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.13 USD resulting in a 52.99% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Bergenbio AS earnings.
Bergenbio AS revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BRRGF net income for the last quarter is −2.35 M USD, while the quarter before that showed −4.65 M USD of net income which accounts for 49.59% change. Track more Bergenbio AS financial stats to get the full picture.
No, BRRGF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 16.00 employees. See our rating of the largest employees — is Bergenbio AS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bergenbio AS EBITDA is −16.05 M USD, and current EBITDA margin is −56.84 K%. See more stats in Bergenbio AS financial statements.
Like other stocks, BRRGF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bergenbio AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bergenbio AS technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bergenbio AS stock shows the strong sell signal. See more of Bergenbio AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.